Skip to main content
. 2016 Dec 18;13:386–394. doi: 10.1016/j.nicl.2016.12.020

Fig. 1.

Fig. 1

Patient with a newly diagnosed glioblastoma. After resection and chemoradiation with temozolomide, MR and FET PET images show residual tumor in the left frontal lobe (baseline imaging for radiotherapy planning) with complete metabolic response 10 weeks after radiotherapy. The residual contrast-enhancing lesion is metabolically inactive (arrows) indicating a post-treatment effect. This is confirmed 22 months later with complete resolution of this lesion.